Spero Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
SPRO$1.03+1.0%Stored close · as of Nov 6, 2026
Contents
Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| March 31, | December 31, | |
|---|---|---|
| 2026 | 2025 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $56,129 | $40,265 |
| Collaboration receivable, current - related party | — | 25,359 |
| Other receivables | 44 | 28 |
| Prepaid expenses and other current assets | 1,439 | 1,634 |
| Total current assets | 57,612 | 67,286 |
| Operating lease right of use assets | 1,256 | 1,480 |
| Other assets | 153 | 153 |
| Total assets | $59,021 | $68,919 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Accounts payable | 217 | 693 |
| Accrued expenses and other current liabilities | 3,142 | 5,578 |
| Operating lease liabilities | 1,967 | 1,956 |
| Income taxes payable | 163 | 383 |
| Deferred revenue, current - related party | — | 258 |
| Total current liabilities | 5,489 | 8,868 |
| Non-current operating lease liabilities | 507 | 939 |
| Other long-term liabilities | 91 | 91 |
| Total liabilities | 6,087 | 9,898 |
| Commitments and contingencies (Note 7) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value; 120,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 57,891,493 shares issued and outstanding as of March 31, 2026 and 56,414,657 shares issued and outstanding as of December 31, 2025 | 58 | 56 |
| Additional paid-in capital | 511,145 | 510,031 |
| Accumulated deficit | (458,269) | (451,066) |
| Total stockholders' equity | 52,934 | 59,021 |
| Total liabilities and stockholders' equity | $59,021 | $68,919 |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(In thousands, except share and per share data)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenues: | ||
| Grant revenue | $— | $763 |
| Collaboration revenue - related party | 258 | 5,099 |
| Collaboration revenue | — | 12 |
| Total revenues | 258 | 5,874 |
| Operating expenses: | ||
| Research and development | 2,909 | 13,606 |
| General and administrative | 4,887 | 6,824 |
| Restructuring | — | 175 |
| Total operating expenses | 7,796 | 20,605 |
| Loss from operations | (7,538) | (14,731) |
| Other income (expense): | ||
| Interest income | 336 | 864 |
| Other income (expense), net | (1) | 1 |
| Total other income (expense), net | 335 | 865 |
| Net loss and comprehensive loss | $(7,203) | $(13,866) |
| Net loss per share attributable to common stockholders, basic and diluted | $(0.13) | $(0.25) |
| Weighted average common shares outstanding, basic and diluted: | 57,281,570 | 55,376,188 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.